Trial · NCT00584909
A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus
NCT00584909, Phase 2, Terminated, University of Alabama at Birmingham; results first posted 2012-03-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus. Trials, record NCT00584909. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00584909
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus
- NCT number
- NCT00584909
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 13 participants, actual
- Lead sponsor
- University of Alabama at Birmingham
- Conditions
- Uterine Cancer
- Interventions
- Paclitaxel and carboplatin combination
- First posted
- 2008-01-02
- Last updated
- 2017-01-27
- Results first posted
- 2012-03-29
- Limitations and caveats
- This study was terminated early due to slow accrual. 4 patients withdrew from the study due to side-effects from the treatment. All 9 patients were evaluable for toxicity and PFS.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Disease-free Survival | 4 years - Median follow up time of 45.3 months | Number of months of survival with no evidence of disease |
| Secondary | Toxicity | 4 years | Toxicity secondary to paclitaxel and carboplatin based upon the NCI common toxicity criteria version |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Disease-free Survival | 4 years - Median follow up time of 45.3 months | months | MEDIAN | |
| SECONDARY | Toxicity | 4 years | participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Disease-free Survival | Paclitaxel + Carboplatin | 50.5 | Full Range 35.5 to 55.9 | months | |
| Toxicity | Paclitaxel + Carboplatin | 9 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Paclitaxel + Carboplatin | 13 | |
| Overall Study | COMPLETED | Paclitaxel + Carboplatin | 9 | |
| Overall Study | NOT COMPLETED | Paclitaxel + Carboplatin | 4 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Neutropenia | Immune system disorders | Paclitaxel + Carboplatin | 6 | 9 | 12 |
| other | Neuropathy | Nervous system disorders | Paclitaxel + Carboplatin | 2 | 9 | 2 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Paclitaxel + Carboplatin | 2 | 9 | 2 |
| other | Gastrointestinal | Gastrointestinal disorders | Paclitaxel + Carboplatin | 1 | 9 | 1 |
| other | Urinary tract infection | Renal and urinary disorders | Paclitaxel + Carboplatin | 1 | 9 | 1 |
| other | Anemia | Blood and lymphatic system disorders | Paclitaxel + Carboplatin | 1 | 9 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Paclitaxel + Carboplatin | ||
| Total, other adverse events | Paclitaxel + Carboplatin | 9 | 9 |
| Total, serious adverse events | Paclitaxel + Carboplatin | 0 | 9 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00584909
GET https://conductscience.org/api/trials/v1/NCT00584909/registered